These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 14693315)

  • 1. Cost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraine.
    Williams P; Reeder CE
    Clin Ther; 2003 Nov; 25(11):2903-19. PubMed ID: 14693315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine.
    McCormack PL; Foster RH
    Pharmacoeconomics; 2005; 23(12):1283-98. PubMed ID: 16336021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point.
    Williams P; Reeder CE
    J Manag Care Pharm; 2004; 10(3):259-65. PubMed ID: 15228377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine.
    Zhang L; Hay JW
    CNS Drugs; 2005; 19(7):635-42. PubMed ID: 15984898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An economic evaluation of rizatriptan in the treatment of migraine.
    Thompson M; Gawel M; Desjardins B; Ferko N; Grima D
    Pharmacoeconomics; 2005; 23(8):837-50. PubMed ID: 16097844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours.
    Adelman JU; Belsey J
    J Manag Care Pharm; 2003; 9(1):45-52. PubMed ID: 14613361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Almotriptan versus rizatriptan in patients with migraine in Spain.
    Leira R; Dualde E; del Barrio H; Machuca M; López-Gil A;
    Headache; 2003; 43(7):734-41. PubMed ID: 12890128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine.
    Dodick DW; Sandrini G; Williams P
    CNS Drugs; 2007; 21(1):73-82. PubMed ID: 17190530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient preference in migraine therapy. A randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan.
    Díez FI; Straube A; Zanchin G
    J Neurol; 2007 Feb; 254(2):242-9. PubMed ID: 17334957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacoeconomic evaluation of oral triptans in the treatment of migraine in Italy.
    Gori S; Morelli N; Acuto G; Caiola F; Iudice A; Murri L
    Minerva Med; 2006 Dec; 97(6):467-77. PubMed ID: 17213783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using patient-centered endpoints to determine the cost-effectiveness of triptans for acute migraine therapy.
    Kelman L; Von Seggern RL
    Am J Ther; 2006; 13(5):411-7. PubMed ID: 16988536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of clinical, service, and cost outcomes of a conversion program of sumatriptan to rizatriptan ODT in primary care patients with migraine headaches.
    Gershovich OE; Billups SJ; Delate T; Hoffman CK; Carroll N
    J Manag Care Pharm; 2006 Apr; 12(3):246-53. PubMed ID: 16623609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Productivity cost benefit to employers of treating migraine with rizatriptan: a specific worksite analysis and model.
    Gerth WC; Sarma S; Hu XH; Silberstein SD
    J Occup Environ Med; 2004 Jan; 46(1):48-54. PubMed ID: 14724478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials.
    Ferrari MD; Roon KI; Lipton RB; Goadsby PJ
    Lancet; 2001 Nov; 358(9294):1668-75. PubMed ID: 11728541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of oral triptan therapy in Sweden.
    Ramsberg J; Henriksson M
    Cephalalgia; 2007 Jan; 27(1):54-62. PubMed ID: 17212684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Almotriptan: a balanced approach to migraine.
    Cull R
    Hosp Med; 2001 Feb; 62(2):96-100. PubMed ID: 11236625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the effects of almotriptan and other triptans on clinical trial outcomes that are meaningful to patients with migraine.
    Mondell BE
    Clin Ther; 2003 Feb; 25(2):331-41. PubMed ID: 12749502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of early versus non-early intervention in acute migraine based on evidence from the 'Act when Mild' study.
    Slof J
    Appl Health Econ Health Policy; 2012 May; 10(3):201-15. PubMed ID: 22320449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on almotriptan in migraine.
    Keam SJ; Goa KL; Figgitt DP
    CNS Drugs; 2002; 16(7):501-7. PubMed ID: 12056924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Almotriptan: a review of its use in migraine.
    Keam SJ; Goa KL; Figgitt DP
    Drugs; 2002; 62(2):387-414. PubMed ID: 11817980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.